Background: Japanese encephalitis virus (JEV) is a major cause of viral encephalitis in South-East Asia and there is a pressing need to develop novel therapeutic options against it.
Introduction
Japanese encephalitis virus (JEV) is a member of the Flavivirus genus in the family Flaviviridae of animal viruses. It is the prototypic member of the JEV serocomplex of flaviviruses that also includes the West Nile, St Louis encephalitis and Murray Valley encephalitis viruses. JEV is transmitted by Culex mosquitoes between wild and domestic birds and pigs. Mosquitoes are vectors as well as a crucial intermediate replicative host for the normal enzootic cycle through birds and pigs, which are the primary hosts. Pigs are amplifying hosts with no evident signs of infection. The virus is transmitted by the infected mosquito bite to humans, which serve as a dead-end host due to the short-duration low viraemia in man. 1 JEV is the causative agent of Japanese encephalitis (JE), which is reported mostly in children in the form of frequent epidemics. The symptoms of JE typically include fever and headache, but other incapacitating manifestations also usually result and frequently involve neurological complications, including brain damage. JE has a major impact on public health in eastern and southern Asia, causing 30 000-50 000 symptomatic cases and 10 000 deaths annually. 2 Recently, JEV has expanded its geographical range into previously non-endemic areas, such as Australia and Pakistan. 3, 4 With several billion people at risk in India, China and South-East Asia, JE represents an international emerging disease of significant concern. 5 A mouse brain-derived inactivated vaccine has been available in limited quantities against JEV, but the safety of the vaccine remains a concern. Although considerable research is ongoing, no effective therapeutics are available to date to treat JE patients. Following the mosquito bite, JEV replicates locally. Unless cleared by the immune system, the virus enters the CNS rapidly, where it replicates efficiently, leading to encephalitis and death. Antivirals inhibiting JEV replication could reduce the viral load early in infection, allowing the immune system to clear the virus and helping the patient to recover from the infection.
The JEV genome is a plus-sense, single-stranded RNA of 11 kb, having a single open reading frame flanked by 5 ′ and 3 ′ non-coding regions. 6 The genome acts as the mRNA and encodes a 3432 amino acid polyprotein that is subsequently cleaved into three structural (capsid, membrane and envelope) and seven non-structural (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5) viral proteins. 7 Attempts have been made to target the viral genome to inhibit JEV replication using different methods with varying success. 8 -12 RNA interference (RNAi) is a cellular mechanism that is induced by double-stranded RNA (dsRNA). Following its recognition by the cellular machinery, dsRNA is cleaved into small interfering RNAs (siRNAs) of 21-23 nucleotides by the enzyme Dicer. Small hairpin RNAs (shRNAs) are also processed in a similar way to produce siRNAs. The siRNAs are then loaded onto a multiprotein complex called RNA-induced silencing complex, which then degrades mRNA by binding to complementary sequences. RNAi thus regulates cellular gene expression and also acts as a defence mechanism against invading viruses. 13 In recent years, RNAi technology has been explored to inhibit the replication of HIV, 14, 15 , and report on the efficacy of an NS5-targeting shRNA (shN8010) that was distinctly superior to shFvE J in both cultured cells and the mouse model of JEV infection.
Materials and methods

Virus and cells
Porcine stable kidney (PS) cells (obtained from NCCS, Pune, India) were grown in minimal essential medium supplemented with 10% fetal bovine serum (FBS) and 0.1% antibiotic cocktail (Gibco). Vero (ATCC, USA) and human embryonic kidney (HEK293A) cells (Qbiogene, USA) were maintained in Eagle's minimum essential medium supplemented with 10% FBS and antibiotics. Neuro-2a, NIH3T3 (both from ATCC, USA) and Plat-E cells (Cell Biolabs, USA) were cultured in Dulbecco's modified essential medium supplemented with 10% FBS, 1 mM sodium pyruvate, 1× non-essential amino acids and antibiotics. The JaOArS982 strain of JEV (obtained from Dr A. Igarashi, Nagasaki University, Japan) was grown in 3-day-old BALB/c mouse brain and titrated by plaque assay on PS cells. 25 
shRNAs
Various target sequences for siRNA-based knockdown of virus replication in the JEV genomic RNA were identified using the Cynix algorithm (Ambion). Synthetic oligonucleotides (Sigma Genosys, USA) corresponding to shRNA cassettes encoding these siRNAs (Table 1) were annealed to generate shRNA-encoding DNA flanked with BamHI and EcoRI sites. This cassette was then cloned between the BamHI and EcoRI sites of the RetroQZsGreen vector (Clontech, USA). The desired clones were identified by restriction mapping and confirmed by nucleotide sequencing.
Preparation of recombinant adenovirus expressing shRNA
The AdEasy system (http://www.coloncancer.org/adeasy.htm) was used to make replication-deficient adenovirus expressing shRNA. The shuttle vector pAdTrack-CMV was modified to have U6 promoter-driven expression of shRNA. To this end, shRNA-encoding plasmids (see above) were used as the template and the shRNA expression constructs under the control of the U6 promoter were PCR amplified with synthetic oligonucleotides (forward: 5 ′ CCGCTAGCCTGGGCAGGAAGAGGGCCTATTTC 3 ′ ; reverse: 5 ′ CCGATATCAATGACCCCGTAATTGATTAC 3 ′ ) to have an NheI site at the 5 ′ end and an EcoRV site at the 3 ′ end. The cytomegalovirus (CMV) promoter and the multiple cloning sites in the pAdTrack-CMV plasmid between the NheI and EcoRI sites were replaced with U6 expression cassettes of shRNAs. The pAdTrack-U6 shRNA clones thus obtained were recombined with pAdEasy-1 by transformation in AdEasier cells (BJ5183 stably transformed with pAdEasy-1). The recombinant plasmids with shRNA expression constructs were used for rescuing recombinant adenovirus by transfection of HEK293A cells. High titre adenovirus was obtained by further passage of primary stock of the recombinant virus in HEK293A cells. Viral titres were determined as plaque-forming units (pfu) on HEK293A cells. 
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Shown above are the nucleotide sequences of synthetic oligonucleotides that were annealed to produce cassettes encoding the shRNA. The bold font corresponds to the target sequence whose location within the target RNA has been identified.
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Preparation of recombinant self-inactivating retrovirus expressing shRNA
For making mouse murine leukaemia virus-based recombinant retrovirus, Plat-E cells were seeded at a density of 2×10 5 cells/well in a 6-well tissue culture plate. The cell monolayers were transfected 18 h later with shRNA-encoding RetroQZsGreen plasmids using Effectene (Qiagen, USA) reagent. Viral supernatants were collected every 24 h while the cells were viable. The virus harvests were pooled and stored at 2708C in aliquots. Viral titres were determined as focus-forming units (ffu) on NIH3T3 cells.
shRNA-mediated inhibition of JEV replication in mouse brain
Four-week-old FvB/J mice (n¼8) were given an intracerebral (ic) injection of 10 6 ffu recombinant retrovirus or 10 7 pfu recombinant adenovirus. One week following the transduction, mice were challenged with 10 8 pfu of JEV (5 LD 50 ) given via intraperitoneal (ip) injection. Virus administration was accompanied with a cranial puncture to produce inflammation, which helps in breaking the blood-brain barrier and JEV entry to the brain. The mice were observed for mortality until 24 days post-infection (p.i.). The Kaplan-Meier estimator was employed to calculate the mean survival time (MST) and the long rank test was used to compute the significance of difference (P values) between the two survival curves. All animal studies were conducted following the approved protocols of the Institutional Animal Care and Ethics Committee.
Results
Inhibition of JEV replication in cultured cells by plasmid-encoded shRNA
Three different shRNAs designed against the JEV genome were tested in HEK293A cells and compared with shFvE J , which was previously shown to inhibit JEV replication in cultured cells and protect mice from virus-induced fatal encephalitis. shC140 and shE1096 targeted genomic sequences encoding the structural proteins capsid and envelope, respectively, whereas shN8010 targeted the sequence encoding the non-structural protein NS5. shFvE J targeted envelope-encoding RNA. 10 shLuc, designed to target Photinus pyralis luciferase mRNA (GenBank accession no. EU684088), was used as a negative control in these experiments.
All the four JEV-specific shRNA-encoding plasmids caused significant suppression of JEV replication in HEK293A cells at 24 h p.i. (Figure 1 ). When cells were infected at a multiplicity of infection (m.o.i.) of 1, shFvE J caused 84% suppression of JEV titres (P¼ 0.013); the comparable value was 88% for shC140 (P ¼ 0.011) and 92% for shE1096 (P ¼ 0.008). The maximum suppression of JEV titres (99%) was caused by shN8010 (P ¼ 0.006). At 36 h p.i., shC140, shE1096 and shN8010 continued to suppress JEV titres by 79% -97% (P,0.05), whereas shFvE J did not affect JEV titres significantly (P ¼ 0.08). At a higher m.o.i. of 10, shC140, shE1096 and shN8010 caused 85%, 83% and 89% suppression of the JEV titres at 24 h p.i. (P,0.05), whereas it was only suppressed by 30% by shFvE J and this was not statistically significant when compared with mocktransfected cells (P ¼ 0.23). At 36 h p.i., compared with mocktransfected cells, JEV titres were 13% -73% lower in presence of shRNA plasmids, although the difference was not statistically significant. Here, also, the maximum suppression of JEV titres was caused by shN8010. In both experiments, JEV titres did not differ significantly between mock and P-shLuc treatment.
These experiments showed that shN8010 could inhibit JEV replication in HEK293A cells by 89% and the suppression of JEV titres by shN8010 was more pronounced than that by shFvE J . This inference was repeatedly drawn from multiple independent experiments conducted at different times.
Inhibition of JEV replication in cultured cells by adenovirus-expressed shRNA
To improve the efficiency of shRNA delivery to cells, replicationdefective recombinant adenovirus capable of synthesizing the shRNA was used. HEK293A cells could not be used in these 
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experiments as recombinant adenovirus actively replicates in these cells, leading to cell death. PS and Vero cells were used in these experiments as they are efficiently transduced by recombinant adenovirus but do not allow virus replication.
Besides the shRNA, recombinant adenovirus used in these experiments expressed the green fluorescent protein (GFP) also. PS and Vero cells showed efficient transduction with recombinant adenovirus at an m.o.i. of 10, as .90% of cells showed GFP-mediated fluorescence 48 h post-transduction. At this stage, cells were infected with JEV ( Figure 2) . In PS cells, shC140, shE1096 and shN8010 caused a very significant suppression of JEV titres (83%, 91% and 99%, respectively) at 24 h p.i. (P,0.05), whereas shLuc did not suppress JEV titres. shFvE J lowered JEV titres by only 10% and this was not statistically significant (P ¼ 0.28). At 36 h p.i., the viral titre suppression continued in a very significant manner (82%-98%) in the presence of shC140, shE1096 and shN8010 (P,0.05). While shFvE J caused 30% suppression of JEV titres (P ¼ 0.01), shLuc also caused 25% suppression of JEV titres at this timepoint (P ¼ 0.004).
In Vero cells, shC140, shE1096 and shN8010 showed 92% -96% suppression of JEV titres at 24 h p.i., while at 36 h p.i. the suppression was 83% -85%. The suppression of JEV titres in all these cases was statistically significant (P,0.05). At 24 h p.i., shFvE J showed 48% suppression of JEV titres (P ¼ 0.11), whereas it was 21% at 36 h p.i. These results also show that the antiviral effect of shN8010 was not due to the induction of an interferon response, as shN8010 showed antiviral activity in Vero cells that lack type I interferon genes.
Inhibition of JEV replication in Neuro-2a cells by virus-expressed shRNA
JEV is a neurotropic virus that actively replicates in neurons. As a prelude to testing the efficacy of shRNAs to inhibit JEV replication in the mouse model, the potential of adenovirus-expressed shRNAs was tested in Neuro-2a cells of mouse neuronal origin.
The adenoviral transduction of Neuro-2a cells was very poor, with only 10% of cells showing GFP expression 48 h posttransduction at an m.o.i. of 10. At a higher adenoviral m.o.i. of 25, 50% -60% of cells showed GFP expression at 120 h posttransduction. At this stage, cells were infected with JEV. At 24 h p.i., adenovirus-encoded shC140, shE1096 and shN8010 caused 97% (P ¼ 0.009), 88% (P ¼ 0.013) and 90% suppression (P ¼ 0.012) of JEV titres, respectively. Adenovirus-encoded shFvE J caused 17% suppression of JEV titres at this stage and this was not statistically significant (P ¼0.70). Adenovirusencoded shLuc did not cause suppression of JEV titres (Figure 3) .
Retroviruses are known to transduce a wide variety of cells, including cells of neuronal origin. As Neuro-2a cells were inefficiently transduced by adenovirus, the use of the retroviral system to deliver shRNA to these cells was examined. Besides shRNA, the recombinant retroviruses used in these experiments also expressed GFP. shRNA-mediated protection of mice against lethal JEV challenge Four-week-old FvB/J mice (n¼ 8) were given ic injection of 10 7 pfu of recombinant adenovirus or were mock treated. One week Similarly, all mice treated with adenovirus encoding shLuc or shFvE J developed symptoms of JEV infection and died within 2 weeks of JEV inoculation; the MSTs here were 10.8 and 11.3 days, respectively, and these were not statistically different from untreated mice. Mice treated with shN8010-encoding adenovirus also developed symptoms of JEV infection; however, these mice showed significantly extended survival (P¼ 0.002) with an MST of 18.6 days. Seven out of eight mice (88%) in this group eventually died, with one mouse surviving.
In a similar experiment, mice were treated ic with 10 6 ffu recombinant self-inactivating retrovirus or mock treated, and 1 week later were challenged with 10 8 pfu of JEV given ip ( Figure 4 ). All mock-treated mice, or those treated with retrovirus expressing shFvE J or shLuc developed symptoms of JEV infection. Seven out of eight mock-treated (MST¼ 12.6 days) or shFvE J -encoding retrovirus-treated (MST ¼13 days) mice died within 2 weeks; the MSTs were not statistically different between these two cases. Six out of eight mice treated with shLuc-encoding retrovirus died, with an MST of 14.2 days. Importantly, none of the mice treated with shN8010-encoding retrovirus showed symptoms of JEV infection at any stage and all of these mice survived the JEV challenge with an MST of .24 days. This difference in the MST of shN8010-treated and mock-treated mice was highly significant (P ¼ 0.0004). 6 ffu recombinant retrovirus (R) (lower panel) in a 100 mL volume. Virus-treated and mock-treated mice were challenged with 10 8 pfu JEV in a 500 mL volume through the ip route 7 days post-transduction. Virus administration was accompanied with a cranial puncture. The mice were observed for mortality until 24 days post-infection. The percentage survival of mice in various groups is shown.
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These data demonstrate the prophylactic potential of shN8010 delivered to mouse brain using a recombinant retrovirus. All the above experiments were repeated at least three times with a similar inference. Figure 4 shows the results of representative experiments.
shRNA-mediated suppression of JEV replication in mouse brain JEV titres in mouse brain were determined to establish whether the protection afforded to mice against JEV challenge by shN8010 was related to the suppression of JEV replication. Four-week-old FvB/J mice (n¼ 5) were treated ic with 10 6 ffu recombinant retrovirus or were mock treated, followed by challenge with 10 8 pfu of JEV given ip 1 week later. JEV titres were determined on days 5 and 6 after JEV inoculation, as mice begin to die around day 7 after virus inoculation in this animal model of JEV infection. On day 5, the mean JEV titre in mocktreated animals was 2.4×10 7 pfu/mL, which rose to 1.4×10 8 pfu/mL by day 6 ( Figure 5 ). Mice treated with shLuc-expressing retrovirus had a mean JEV titre of 1.3×10 7 and 5.1×10 7 pfu/mL on days 5 and 6, respectively, and these did not differ significantly from those in the mock-treated mice (P ¼ 0.312 and P ¼0.164, respectively). Compared with the mock-treated mice, shN8010-expressing retrovirus-treated mice had 4 log lower JEV titres. Thus, mice treated with shN8010-expressing retrovirus had a mean JEV titre of 6.2×10 2 and 1.0×10 3 pfu/mL on days 5 and 6, respectively, and these were very significantly different from those in the mock-treated mice (P,0.0001 and P,0.0001, respectively).
Discussion
Nucleic-acid-based antiviral agents are rapidly finding favour as a potential strategy for inhibiting virus replication. These agents are usually designed to induce targeted cleavage of the viral genome or to anneal to and block its replication. Sequencespecific approaches for the inhibition of virus replication are appealing, in part because of the low likelihood of target sequence homology between the pathogen and host; thus, minimizing the potential for toxicity from cross-reactivity. Furthermore, using nucleic-acid-based compounds to target sequences that are highly conserved between viral strains or species raises the prospect of developing an agent with a broad antiviral spectrum. Reports from our laboratory and others have previously shown successful inhibition of JEV and other flaviviruses using different nucleic acid complementaritybased inhibitory approaches, such as DNAzyme, 9 RNAzyme 22 and antisense nucleic acid. 8,11,26 -29 siRNAs have emerged as one of the most potent RNA knockdown strategies in recent times and therefore present as one of the most promising RNA-virus-inhibiting tools. siRNAs have been successfully used to inhibit the replication of different flaviviruses in cultured cells and animal models. As for JEV, Kumar et al. 10 described an siRNA targeting the envelope gene of JEV. They showed that a single intracranial administration of lentivirus-delivered shRNA (shFvE J ) or a corresponding lipid-complexed siRNA before JEV challenge protected mice from lethal encephalitis. Subsequently, Liu et al. 30 described siRNAs that could effectively down-regulate the expression of NS1 protein in JEV-infected cells as measured by immunofluorescence, although suppression was not quantified. In another study, Qi et al. 12 described NS5-targeting siRNAs, the best of which showed an 80% reduction of the envelope protein level in JEV-infected cells as measured by western blotting. In both these latter studies, the effect of siRNAs on JEV replication in cells as measured by viral titres or in an animal model was not studied.
In this study, we designed three novel shRNAs targeting capsid, envelope and NS5 genes of JEV, and examined their antiviral potential in cultured cells and mice in comparison with shFvE J , for which the quantitative efficacy data in cultured cells and mice exist. Our work showed that shN8010 targeting the NS5 gene was most potent as it caused significant suppression of JEV replication in HEK293A, PS, Vero and Neuro-2a cells using different delivery methods. We reproducibly noted only poor inhibition of JEV replication in HEK293A cells by shFvE J when delivered in the form of a plasmid. Kumar et al. 10 did not study plasmid-delivered shFvE J in cell lines, although they reported robust protection of cell lines from JEV infection when corresponding lipid-complexed siRNA was used. Again, in our study shFvE J delivered through recombinant adenovirus caused siRNA suppression of JEV replication only minimal inhibition of JEV replication, whereas shN8010 suppressed JEV titres by 95% and 99% in Vero and PS cells, respectively. In Neuro-2a cells also, adenovirus-delivered shFvE J caused very little suppression of JEV replication whereas shN8010 caused 90% suppression of JEV titres. Similarly, retrovirusdelivered shFvE J suppressed JEV titres in Neuro-2a cells by 25% (P ¼ 0.43) whereas shN8010 caused 90% suppression (P ¼ 0.001) of JEV titres. Kumar et al. 10 reported complete abrogation of JEV replication in Neuro-2a cells by lentivirus-delivered shFvE J . It may be noted that the lentivirus used in their experiments was pseudotyped with rabies virus glycoprotein (RVG), which may have contributed to a better delivery of siRNA to neuronal cells.
The antiviral activity of shN8010, and the lack of it by shFvE J in cultured cells, was reflected in their ability to protect mice against lethal JEV challenge. Thus, mice treated intracerebrally with adenovirus-delivered shFvE J died with an MST of 11.3 days and showed no protection when challenged with a lethal JEV dose, whereas those treated with shN8010 had an MST of 18.6 days, although none of the mice survived the challenge. Interestingly, mice treated intracerebrally with retrovirusdelivered shN8010 showed an MST of .24 days and showed 100% protection against lethal JEV challenge, whereas retrovirus-delivered shFvE J failed to protect JEV-challenged animals. Our experiments also showed that JEV replicated to significantly lower titres in brains of mice treated with retrovirusdelivered shN8010 and this was related to JEV-specific RNAi activity induced by shN8010, as retrovirus-delivered shLuc failed to affect JEV titres in mouse brain. As opposed to our results, Kumar et al. 10 reported complete protection of mice treated with lentivirus-delivered shFvE J against lethal JEV challenge, although this may be related to efficient shRNA delivery due to the virus pseudotyping with RVG. This may also be related to the differences in the ability of the vector systems used in the two studies to productively infect non-dividing cells, such as neurons in mouse brain. shFvE J , which was previously documented to be efficient in inhibiting viral replication in JEV-and West Nile virus-infected cell lines as well as mice, seems ineffective in our experimental system. For us this was a major concern, but these results have been reproduced several times. The differences observed here in the efficacy of shFvE J may be related to differences in the virus assay system, virus strains, transfection reagents and mouse strain used. For example, we measured JEV titres in transfected or transduced cell monolayers by plaque assays, whereas Kumar et al. 10 studied virus replication by anti-JEV fluorescence labelling of transduced cells. While in the former method untransfected/untransduced cells will allow JEV replication uninhibited and will contribute to overall extracellular virus titres, the latter method only targets those cells that have been transduced and thus shows significant or complete abrogation of JEV replication. While Kumar et al. 10 used the Nakayama strain of JEV, we used the JaOArS982 strain. Although the target sequence for shFvE J is conserved between the two strains, the accessibility of siRNA to the target due to the potential differences in the RNA structure owing to mutations between the two strains cannot be ruled out. Similarly, the use of different transfection reagents and mouse strains may affect the efficacy of an shRNA, but these are unlikely to make it altogether ineffective.
There are currently 84 NS5 sequences from different JEV strains in the GenBank database. Of these, 77 show 100% conservation of the 19 nucleotide sequence targeted by shN8010, while 7 show 84% identity where the first 3 nucleotides were different. While there is a stringent homology requirement of the critical central residues for the efficacy of an siRNA, many peripheral nucleotide changes are well tolerated. 31, 32 In fact, Martinez and Tuschl 32 showed that target mismatch of four nucleotides at either end of the siRNA is well tolerated. These data suggest that shN8010 might be effective against all JEV isolates, although we are yet to test it against any JEV strain other than JaOArS982. It is not clear how readily shRNA-resistant virus may be selected. To minimize this possibility, it may be prudent to use more than one shRNA for any therapeutic application.
Our results show that retrovirus-delivered shN8010 caused significant suppression of JEV replication in mouse brain and fully protected the mice from lethal JEV challenge. These data thus reinforce the potential of siRNA-based therapeutic intervention to treat JE infection. However, the delivery of siRNA in a clinical scenario still remains a big challenge, and novel methods applicable to humans need to be developed that ensure the stability of siRNA and its efficient delivery to the specific target cells. It has been shown recently that a small peptide derived from RVG fused to a highly positively charged 9-mer polyarginine (RVG-9R) efficiently crossed the blood -brain barrier, and effectively delivered siRNA to macrophages, dendritic cells and neuronal cells. 21, 33 It may be noted that all of these cell types are involved in JEV infection in vivo. More recently, RVG-targeted exosomes loaded with siRNA showed effective gene knockdown in the mouse model, specifically in neurons, microglia and oligodendrocytes in the brain. 34 In the next step, the efficacy of shN8010 or the corresponding siRNA in the mouse model will be tested using methods that will deliver it to the brain when injected peripherally.
An interesting observation in our work was that the suppression of JEV in cultured cells was often greater than the proportion of cells transduced with the inhibitory siRNA (shN8010). For example, Vero cells where transfection efficiency was 90% showed .99% suppression of the JEV titre and Neuro-2a cells that showed 60% transduction had 97% suppression of the JEV titre. Similarly, 10 6 ffu of recombinant retrovirus used in the present study would infect only a small proportion of brain cells in the mouse model of JEV infection, yet it provided mice with complete protection against virus infection. It may be noted that microRNAs are known to shuttle between cells via exosomes 35, 36 and a recent report described exosome-mediated siRNA delivery to mouse brain. 34 It may be interesting to investigate if the enhanced suppression of JEV titres in cultured cells and mouse brain may have resulted from siRNA transport to neighbouring cells through microvesicles.
siRNAs have been shown to be functional in mosquito cells against dengue virus.
22,24 Thus, JEV siRNA could be expressed in transgenic mosquitoes to potentially block the virus transmission cycle. While complete suppression of JEV infectivity in a transgenic mosquito may not be achieved, a significant reduction of virus replication could result in a decreased ability of mosquitoes to transmit the virus to man. This may constitute a novel approach to JEV control through transgenic mosquitoes.
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